Abstract
The efficacy and safety of risperidone, haloperidol, and thioridazine for treating dementia-associated behavioral disturbances were evaluated in a retrospective study of 186 patients aged 65 years or older with DSM-III-R or DSM-IV diagnoses of Alzheimer's dementia, senile dementia NOS, or organic brain syndrome. Study patients were selected from the charts of 12,000 residents of 60 long-term-care facilities in New Jersey if they were treated with one of the three agents for behaviors dangerous to themselves or others. The 186 selected patients included 60 treated with risperidone (mean, 1 mg/day), 83 with haloperidol (mean, 2 mg/day), and 43 with thioridazine (mean, 33 mg/day). Target behaviors were violence (74 patients), shouting (31), delusions (26), paranoia (19), pacing (3), and mixed behaviors (33). Target behaviors improved in 94% of patients given risperidone, 65% given haloperidol, and 67% given thioridazine (p < .001). Treatment failures (treatment discontinued in patients because of side effects or no improvement) were more frequent in patients started on haloperidol (28) or thioridazine (15) than on risperidone (3). Extrapyramidal symptoms were reported in 7% of patients taking risperidone, 22% taking haloperidol, a...Continue Reading
Citations
Dec 24, 2003·Journal of Psychiatric Research·Dilip V Jeste, Christian R Dolder
Jan 7, 2004·Journal of the American Medical Directors Association·Peter D FeldmanAlan Breier
Nov 26, 1999·The New England Journal of Medicine·R Mayeux, M Sano
Sep 12, 2003·The New England Journal of Medicine·Claudia H Kawas
Feb 24, 2001·Pharmacotherapy·C H Rojas-FernandezC MacKnight
Oct 26, 2000·Clinical Therapeutics·P N TariotI W Rak
Mar 6, 2003·Journal of Clinical Pharmacology·Qinying ZhaoJean-Loup Parier
Sep 17, 2002·Journal of Geriatric Psychiatry and Neurology·Joseph H Friedman, Hubert H Fernandez
Dec 19, 2001·International Journal of Geriatric Psychiatry·J S StreetA Breier
Feb 24, 2001·International Clinical Psychopharmacology·I Schweitzer
Dec 19, 1998·Neuroreport·D MoecharsF Van Leuven
Dec 24, 2002·International Journal of Geriatric Psychiatry·Y A L PijnenburgM N Rossor
Jul 2, 1999·International Journal of Geriatric Psychiatry·A WimoM Grafstrom
Nov 18, 2006·Drugs & Aging·Alistair Burns, Peter P De Deyn
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Zaudig
Jun 1, 2002·Drugs & Aging·Sandra S KindermannDilip V Jeste
Apr 9, 2005·Drugs & Aging·I Barton Frenchman
May 31, 2007·Clinical Drug Investigation·Pietro GareriGiovambattista De Sarro
Jul 28, 2009·Australian and New Zealand Journal of Public Health·Anna HyndJames Semmens
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Dec 6, 2000·Journal of Clinical Psychopharmacology·E WeissW W Fleischhacker
Nov 1, 2001·The Cochrane Database of Systematic Reviews·V KirchnerR J Harvey
May 5, 2000·The Cochrane Database of Systematic Reviews·V KirchnerR J Harvey
Jan 27, 2006·The Cochrane Database of Systematic Reviews·R G MarriottS Waddingham